Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

By James Larkin, F. S. Hodi, J. Wolchok. New England Journal of Medicine, 2015

4,195 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/141eca4a5ac35519188d25e1956c3fd3d4f31b79

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. J. Wolchok
2. M. Postow
3. C. Robert
4. Yang Xie
5. M. Lacouture
6. Benjamin Haaland
7. J. Goldberg
8. T. Gajewski

In Oncology

1. J. Wolchok
2. Antoni Ribas
3. M. Postow
4. M. Hellmann
5. C. Robert
6. Ton N. Schumacher
7. K. Flaherty
8. F. Hodi

Citations in the corpus

• Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab (2017, background): “However, this combination is much more toxic than each of the drugs given as monotherapy, with close to 60% grades 3–5 adverse events, many of them being severe colitis, and interruption of treatment in 40% of patients because of toxicity [43, 44].”
• Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. (2017, background): “of doses (range) 4 (1-38) Best objective response† CR/PR 25 PD 2 SD 14”
• Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab (2016, background): “Anti-PD-1 antibodies are more effective and less toxic than ipilimumab [1, 2].”
• Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis (2017, background): “Both CTLA-4 and PD-1 play a key role in the maintenance of immunological tolerance to self-antigens, preventing autoimmune disorders.(5-8) Therefore, at the same time that ICI are able to unleash T cells to fight cancer, they also can trigger autoimmunelike manifestations in different organ systems,”
• Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022, background): “Therefore, ipilimumab is commonly administrated at a reduced dose [154], which might weaken the efficacy of combination therapy.”
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. (2016, methodology): “[36] III Melanoma 945 (N only = 316, N + I = 314, I alone = 315) N (3 mg/kg every 3 weeks) versus I (3 mg/kg every 3 weeks × 4) versus N + I (N: 1 mg/kg × 4 doses + I then N: 3 mg/kg every 3 weeks × 4, or 3 mg/kg from cycle 3 on every 2 weeks) Total = 96% (n = 299) Diarrhea (44%, n = 138) Fatigue (3”
• Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (2017, background): “Severe irAEs tend to occur more commonly with combination ICI therapy [40].”
• Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. (2018, neutral): “3 (1-57) 10 (43) 9 (69) Pulmonary 6 (5) 1 (1) 10.”
• Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018, background): “Although PD-L1 expression on tumor cells was correlated with treatment efficacy in melanoma patients (67, 108), it was not in patients with squamous cell carcinoma, non-small cell lung cancer and Merkel cell carcinoma (70, 72, 74).”